Prevalent mutations in prostate cancer

• Published in: Journal of cellular biochemistry Vol. 97; no. 3; pp. 433 - 447
• Main Author: Dong, Jin-Tang
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 15.02.2006
• Subjects: amplification; Animals; deletion; haploinsufficiency; Humans; Loss of Heterozygosity; Male; mutation; Mutation - genetics; oncogene; prostate cancer; Prostatic Neoplasms - genetics; tumor suppressor gene; Tumor Suppressor Proteins - genetics
• ISSN: 0730-2312; 1097-4644
• DOI: 10.1002/jcb.20696

Quantitative and structural genetic alterations cause the development and progression of prostate cancer. A number of genes have been implicated in prostate cancer by genetic alterations and functional consequences of the genetic alterations. These include the ELAC2 (HPC2), MSR1, and RNASEL (HPC1) genes that have germline mutations in familial prostate cancer; AR, ATBF1, EPHB2 (ERK), KLF6, mitochondria DNA, p53, PTEN, and RAS that have somatic mutations in sporadic prostate cancer; AR, BRCA1, BRCA2, CHEK2 (RAD53), CYP17, CYP1B1, CYP3A4, GSTM1, GSTP1, GSTT1, PON1, SRD5A2, and VDR that have germline genetic variants associated with either hereditary and/or sporadic prostate cancer; and ANXA7 (ANX7), KLF5, NKX3‐1 (NKX3.1), CDKN1B (p27), and MYC that have genomic copy number changes affecting gene function. More genes relevant to prostate cancer remain to be identified in each of these gene groups. For the genes that have been identified, most need additional genetic, functional, and/or biochemical examination. Identification and characterization of these genes will be a key step for improving the detection and treatment of prostate cancer. © 2005 Wiley‐Liss, Inc.